Literature DB >> 2394834

Effects of interleukin 2 on cardiac function in the isolated rat heart.

P A Sobotka1, J McMannis, R I Fisher, D G Stein, J X Thomas.   

Abstract

Adoptive immunotherapy with IL 2 is associated with severe cardiovascular toxicities including peripheral and pulmonary edema, hypotension decreased systemic vascular resistance, increased heart rate, and an increased cardiac index. The purpose of this investigation was to determine whether IL 2 alone or in combination with lymphokine-activated killer cells (LAK) cells depress cardiac function using the isolated, perfused, working rat heart preparation. Male Sprague-Dawley rats (250-350 g) were anesthetized and the hearts were removed and placed on the perfusion apparatus. Hearts were perfused with oxygenated Krebs-Henseleit buffer (KHB), or oxygenated KHB containing IL 2 alone, IL 2-Media (cell culture media supplemented with 1,500 U IL 2/ml), LYMPH (cell culture media from cultured mononuclear cells from healthy volunteers), or LAK (cell culture media from cultured lymphocytes harvested from patients receiving IL 2/LAK in the presence of 1,500 U/ml IL 2). The cells were removed before perfusion (n = 9). Cardiac output and coronary flow were measured at 20-min intervals with preload constant (afterload varied or afterload constant (preload varied). The results indicate a significant depression in cardiac function in hearts treated with LAK. This depression was evident at 20 min and was more pronounced at 60 min. Washout of the KHB plus LAK reversed this depression. Thus, IL 2-stimulated/cultured human mononuclear cells produce a soluble factor that produces a reversible severe depression of cardiac function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2394834      PMCID: PMC296801          DOI: 10.1172/JCI114783

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma.

Authors:  L R Deyton; R E Walker; J A Kovacs; B Herpin; M Parker; H Masur; A S Fauci; H C Lane
Journal:  N Engl J Med       Date:  1989-11-02       Impact factor: 91.245

2.  Effect of pressure development on oxygen consumption by isolated rat heart.

Authors:  J R Neely; H Liebermeister; E J Battersby; H E Morgan
Journal:  Am J Physiol       Date:  1967-04

3.  Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

Authors:  M Rosenstein; S E Ettinghausen; S A Rosenberg
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

4.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

5.  Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.

Authors:  A Belldegrun; D E Webb; H A Austin; S M Steinberg; D E White; W M Linehan; S A Rosenberg
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

6.  Clinical effects and toxicity of interleukin-2 in patients with cancer.

Authors:  M T Lotze; Y L Matory; A A Rayner; S E Ettinghausen; J T Vetto; C A Seipp; S A Rosenberg
Journal:  Cancer       Date:  1986-12-15       Impact factor: 6.860

7.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

8.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

9.  High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings.

Authors:  M T Lotze; A E Chang; C A Seipp; C Simpson; J T Vetto; S A Rosenberg
Journal:  JAMA       Date:  1986-12-12       Impact factor: 56.272

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  5 in total

1.  Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium.

Authors:  R Schulz; E Nava; S Moncada
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

2.  The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta.

Authors:  D J Pinsky; B Cai; X Yang; C Rodriguez; R R Sciacca; P J Cannon
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

3.  The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha.

Authors:  R Schulz; D L Panas; R Catena; S Moncada; P M Olley; G D Lopaschuk
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

4.  Myocardial calcium-independent nitric oxide synthase activity is present in dilated cardiomyopathy, myocarditis, and postpartum cardiomyopathy but not in ischaemic or valvar heart disease.

Authors:  A J de Belder; M W Radomski; H J Why; P J Richardson; J F Martin
Journal:  Br Heart J       Date:  1995-10

Review 5.  Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress.

Authors:  Nabeel Quryshi; Laura E Norwood Toro; Karima Ait-Aissa; Amanda Kong; Andreas M Beyer
Journal:  Int J Mol Sci       Date:  2018-03-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.